A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).

Trial Profile

A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART).

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2013

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Sep 2013 Results have been reported in a Sumagen Canada and University of western Ontario media release.
    • 03 Sep 2013 Status changed from recruiting to completed based on information reported in a Sumagen Canada and University of Western Ontario media release.
    • 02 Jul 2013 Planned End Date changed from 1 Nov 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top